Skip to main content
. 2015 May 1;94(17):e730. doi: 10.1097/MD.0000000000000730

FIGURE 3.

FIGURE 3

HBeAg and HBsAg clearance rates at week 48, 24 weeks post–PEG-IFN, and 120 weeks after PEG-IFN therapy initiation in patients with 12W and 24W EVR and non-EVR. HBeAg seroconversion and HBsAg clearance rates are shown in the PEG-IFN ST and PEG-IFN SOT groups at week 48 and 24 weeks post-PEG-IFN treatment, 120 weeks after PEG-IFN therapy initiation are shown for patients with EVR (A, B) and non-EVR patients (C, D). ADV = adefovir, EVR = early virological response, HBeAg = hepatitis B virus e antigen, HBsAg = hepatitis B virus surface antigen, PEG-IFN SOT = pegylated interferon-α-2a stepwise optimization treatment, PEG-IFN ST = pegylated interferon-α-2a standard therapy, W = week.